WELCOME

I am delighted to introduce our catalogue comprising everything you need to know about Future Science Group (FSG).

Our journals, publishing solutions and digital sites continue to service a mixed professional audience, whether authors, librarians, sponsors, or various other science and medical professionals.

The last year has been an exciting period of growth for FSG, with a rise of over 160,000 full-text downloads (more than 1.1 million in the last 12 months). We have also been very active with Open Access – our two recent journal additions, Concussion (P.9) and Future Science OA (P.14), continue to shine. And we’re excited about our two latest journal launches; the International Journal of Pharmacokinetics (P.7) serves the needs of all professionals within the field of drug development, while the Journal of 3D Printing in Medicine (P.7), very much in keeping with our ethos, focuses on a truly cutting-edge field of medicine.

Although growth is great, commitment to our communities is always dear to us. Closely linked to the Journal of 3D Printing in Medicine, 3DMedNet (P.34) is a key addition to our eCommunities, including Bioanalysis Zone (over 8000 members), Oncology Central (more than 5000 members) and Neurology Central; all three of which have launched their very own apps.

Finally, we are committed to offering all of our customers the very best in customer service. Our recent partnership with Kudos will help authors increase the impact and reach of their research, and we are producing more and more webinars (see P.35).

I look forward to working with you in the year ahead.

Phil Garner
Managing Director, Future Science Group
OUR JOURNAL PORTFOLIO

FSG publishes a constantly expanding group of journals in cutting-edge areas of postgenomic scientific and medical information. Many of our titles are indexed on MEDLINE, Thomson’s Science Citation Index Expanded, EMBASE, Chemical Abstracts and Scopus. While the topics are diverse, all publications are:

Original and Timely – blending commissioned and unsolicited content, whether reviews, research or commentaries, to ensure that readers are kept comprehensively updated on the latest advances and techniques in bioscience and clinical practice, whatever their discipline.

Easy-To-Read – we have produced a specially designed reader-friendly layout for all content to speed up learning and save time.

Visible and Accessible Globally – to ensure 24/7 access, all our titles are hosted by Atypon – a market leader in content management platforms.
**FUTURE MEDICINE AT-A-GLANCE**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Biomarkers in Medicine</td>
<td>Yes</td>
<td>2.179</td>
<td>11,054</td>
<td>~30%</td>
<td>9</td>
</tr>
<tr>
<td>Breast Cancer Management</td>
<td>No</td>
<td>N/A</td>
<td>1431</td>
<td>~70%</td>
<td>9</td>
</tr>
<tr>
<td>CNS Oncology</td>
<td>Yes</td>
<td>N/A</td>
<td>3302</td>
<td>&gt;80%</td>
<td>9</td>
</tr>
<tr>
<td>Colorectal Cancer</td>
<td>No</td>
<td>N/A</td>
<td>961</td>
<td>&gt;80%</td>
<td>9</td>
</tr>
<tr>
<td>Concussion</td>
<td>No</td>
<td>N/A</td>
<td>486</td>
<td>&gt;80%</td>
<td>9</td>
</tr>
<tr>
<td>Epigenomics</td>
<td>Yes</td>
<td>4.044</td>
<td>13,495</td>
<td>~70%</td>
<td>9</td>
</tr>
<tr>
<td>Future Cardiology</td>
<td>Yes</td>
<td>N/A</td>
<td>9137</td>
<td>&gt;70%</td>
<td>10</td>
</tr>
<tr>
<td>Future Microbiology</td>
<td>Yes</td>
<td>3.637</td>
<td>22,910</td>
<td>~50%</td>
<td>10</td>
</tr>
<tr>
<td>Future Neurology</td>
<td>No</td>
<td>N/A</td>
<td>4376</td>
<td>&gt;80%</td>
<td>10</td>
</tr>
<tr>
<td>Future Oncology</td>
<td>Yes</td>
<td>2.129</td>
<td>34,450</td>
<td>~50%</td>
<td>10</td>
</tr>
<tr>
<td>Future Virology</td>
<td>No</td>
<td>0.886</td>
<td>5703</td>
<td>~50%</td>
<td>10</td>
</tr>
<tr>
<td>Hepatic Oncology</td>
<td>No</td>
<td>N/A</td>
<td>770</td>
<td>&gt;80%</td>
<td>10</td>
</tr>
<tr>
<td>Immunotherapy</td>
<td>Yes</td>
<td>2.083</td>
<td>12,742</td>
<td>&gt;70%</td>
<td>11</td>
</tr>
<tr>
<td>International Journal of Endocrine Oncology</td>
<td>No</td>
<td>N/A</td>
<td>551</td>
<td>&gt;80%</td>
<td>11</td>
</tr>
<tr>
<td>International Journal of Hematologic Oncology</td>
<td>No</td>
<td>N/A</td>
<td>764</td>
<td>&gt;80%</td>
<td>11</td>
</tr>
<tr>
<td>(NEW) Journal of 3D Printing in Medicine</td>
<td>No</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>7</td>
</tr>
<tr>
<td>Journal of Comparative Effectiveness Research</td>
<td>Yes</td>
<td>1.075</td>
<td>4508</td>
<td>~70%</td>
<td>11</td>
</tr>
<tr>
<td>Lung Cancer Management</td>
<td>No</td>
<td>N/A</td>
<td>1108</td>
<td>&gt;80%</td>
<td>11</td>
</tr>
<tr>
<td>Melanoma Management</td>
<td>No</td>
<td>N/A</td>
<td>643</td>
<td>&gt;80%</td>
<td>11</td>
</tr>
<tr>
<td>Nanomedicine</td>
<td>Yes</td>
<td>4.889</td>
<td>34,926</td>
<td>~40%</td>
<td>11</td>
</tr>
<tr>
<td>Neurodegenerative Disease Management</td>
<td>Yes</td>
<td>N/A</td>
<td>4823</td>
<td>&gt;80%</td>
<td>12</td>
</tr>
<tr>
<td>Pain Management</td>
<td>Yes</td>
<td>N/A</td>
<td>5500</td>
<td>&gt;80%</td>
<td>12</td>
</tr>
<tr>
<td>Personalized Medicine</td>
<td>No</td>
<td>1.00</td>
<td>5000</td>
<td>&gt;60%</td>
<td>12</td>
</tr>
<tr>
<td>Pharmacogenomics</td>
<td>Yes</td>
<td>2.71</td>
<td>24,931</td>
<td>&gt;80%</td>
<td>12</td>
</tr>
<tr>
<td>Regenerative Medicine</td>
<td>Yes</td>
<td>2.602</td>
<td>11,702</td>
<td>~50%</td>
<td>12</td>
</tr>
</tbody>
</table>
FUTURE SCIENCE AT-A-GLANCE

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Bioanalysis</td>
<td>Yes</td>
<td>2.813</td>
<td>57,836</td>
<td>&gt;60%</td>
<td>14</td>
</tr>
<tr>
<td>Future Medicinal Chemistry</td>
<td>Yes</td>
<td>3.345</td>
<td>25,424</td>
<td>~50%</td>
<td>14</td>
</tr>
<tr>
<td>Future Science OA</td>
<td>No</td>
<td>N/A</td>
<td>2432</td>
<td>&gt;80%</td>
<td>14</td>
</tr>
<tr>
<td>(NEW) International Journal of Pharmacokinetics</td>
<td>No</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>7</td>
</tr>
<tr>
<td>Pharmaceutical Patent Analyst</td>
<td>Yes</td>
<td>N/A</td>
<td>3432</td>
<td>&gt;80%</td>
<td>14</td>
</tr>
<tr>
<td>Therapeutic Delivery</td>
<td>Yes</td>
<td>N/A</td>
<td>9825</td>
<td>&gt;80%</td>
<td>14</td>
</tr>
</tbody>
</table>

NEW TO FUTURE MEDICINE

Journal of 3D Printing in Medicine

Poised at the brink of an exciting new era in healthcare, The Journal of 3D Printing in Medicine encompasses all aspects of bioprinting and 3D printing of relevance to medicine. It will provide a forum for original research, review and commentary in this fast-moving, inter-disciplinary research area that promises new levels of precision, personalization and cost efficiency.

Frequency: 4 per year
Dietmar W Hutmacher
Editor-in-Chief

NEW TO FUTURE SCIENCE

International Journal of Pharmacokinetics

Original research studies and reviews addressing all issues relating to the preclinical and clinical pharmacokinetic study of potential therapeutics, serving the need of professionals within the field of drug development.

Frequency: 4 per year
MEDLINE-indexed
Impact factor (2015)

Biomarkers in Medicine
Frequency: 12 per year
Senior Editors:
Andre Terzic
Scott Waldman
Hot topics in all fields of medical biomarker research

CNS Oncology
Frequency: 4 per year
Senior Editors:
Alba A Brandes
Henry S Friedman
Clinical and translational research on, and management of, tumors of the central nervous system

Concussion
Rolling publication
The first international, open access journal to focus on this fast-developing field

Breast Cancer Management
Frequency: 4 per year
Senior Editors:
J Michael Dixon
V Craig Jordan
Provides cutting-edge research and management perspectives on this widespread disease

Colorectal Cancer
Frequency: 4 per year
Senior Editor:
Heinz-Josef Lenz
Presents reviews, analysis and expert commentary on developments in this fast-moving field

Epigenomics
Frequency: 12 per year
Senior Editors:
James G Herman
Jörg Tost
Focus on the description and analysis of epigenetic changes across the genome and their role in health and disease
Future Cardiology
Frequency: 6 per year
Covers advances in basic, translational and clinical cardiology research

Future Neurology
Frequency: 4 per year
Senior Editor: Steven R Levine
Includes advances in basic, translational and clinical neurology research

Future Virology
Frequency: 12 per year
Senior Editor: Mark Wainberg
Latest updates in virology, infectious disease and immunology analysis

Future Microbiology
Frequency: 16 per year
Senior Editors: Richard A Calderone B Brett Finlay
Covers medical microbiological areas including all pathogen types and microbe–host interactions

Future Oncology
Frequency: 30 per year
Senior Editors: Ron Allison Alan Dicker
Provides updates on oncology research, ranging from the bench to the bedside

Future Virology
Frequency: 12 per year
Senior Editor: Mark Wainberg
Latest updates in virology, infectious disease and immunology analysis

Hepatic Oncology
Frequency: 4 per year
Senior Editor: Richard S Finn
Addresses all types of cancer of the liver, in both the adult and pediatric populations

For more information go to www.future-science-group.com
Immunotherapy
Frequency: 16 per year
Senior Editors:
Yutaka Kawakami
Francesco M Marincola
Kwong Tsang
David C Wraith
Therapeutics that harness the immune system to combat disease

International Journal of Hematologic Oncology
Frequency: 4 per year
Senior Editor:
Michele Baccarani
Discussion and analysis of emerging advancements in the management of blood cancers

Journal of Comparative Effectiveness Research
Frequency: 8 per year
Senior Editors:
Sheldon Greenfield
Eugene C Rich
The only MEDLINE-indexed journal focused specifically on comparative effectiveness research

Melanoma Management
Frequency: 4 per year
Senior Editors:
Kevin B Kim
John Thompson
Focuses on clinical aspects of treating a patient with melanoma

International Journal of Endocrine Oncology
Frequency: 4 per year
Senior Editors:
Electron Kebebew
Karel Pacak
Specific focus on cancers of the endocrine system

(NEW) Journal of 3D Printing in Medicine
Editor-in-Chief
Dietmar W Hutmacher
Encompasses all aspects of bioprinting and 3D printing of relevance to medicine. See P.7.

Lung Cancer Management
Frequency: 4 per year
Editor-in-Chief:
David J Sugarbaker
Recent research findings and advances in clinical practice in lung cancer

Nanomedicine
Frequency: 24 per year
Senior Editors:
Kostas Kostarelos
Charles R Martin
Advances in medical nanoscale-structured material and devices
Neurodegenerative Disease Management
Frequency: 6 per year
Associate Editors:
Anthony Schapira
Bruno Dubois
Managing neurodegenerative disease in practice

Personalized Medicine
Frequency: 6 per year
Editors:
Edward Abrahams
Geoffrey Ginsburg
Howard L McLeod
Cutting-edge advances in precision medicine are put into a clinical context alongside arising ethical, policy and regulatory issues

Regenerative Medicine
Frequency: 8 per year
Senior Editor:
Chris Mason
Up-to-date research for the translation of regenerative medicine from bench to bedside

Pain Management
Frequency: 6 per year
Senior Editor:
Martin Grabois
Latest research findings and reviews in pain medicine

Pharmacogenomics
Frequency: 18 per year
Senior Editors:
David Gurwitz
Howard McLeod
Research and comment on the role of genomics in drug response

“Professional staff, fast publication process. Highly recommended.”
– Ming Li, Biogen, USA

For more information go to www.future-science-group.com
Applied science and intellectual property issues in R&D

Bioanalysis
Frequency: 24 per year
Senior Editor:
Neil Spooner
Scientific, technical and regulatory developments in bioanalysis

Future Medicinal Chemistry
Frequency: 18 per year
Senior Editors:
Jonathan Baell
Iwao Ojima
Design of small-molecule bioactive agents and the identification of therapeutic targets

Future Science OA
Rolling Publication
Senior Editors:
Benoit Arsenault
Ian A Blair
Paul N Span
High-quality Gold Open Access journal, covering all research of relevance to human health

Pharmaceutical Patent Analyst
Frequency: 6 per year
Senior Editors:
Lyn Jones
Andrew McKnight
David Rotella
High-impact scientific reviews of recent patents, discussed within the context of other R&D advances

International Journal of Pharmacokinetics
Editors:
Karel Allegaert
Jasper Dingemanse
Nuggehally R Srinivas
Raman Venkataramanan
Original research studies and reviews addressing all issues relating to the preclinical and clinical pharmacokinetic study of potential therapeutics. See P.7.

Therapeutic Delivery
Frequency: 12 per year
Comprehensive coverage of all aspects of the evolving drug delivery field
Diverse audience

**FUTURE MEDICINE**

- Hospital (7%)
- Government (8%)
- Corporate (11%)
- Academic (72%)
- Other (2%)

**FUTURE SCIENCE**

- Hospital (1%)
- Government (6%)
- Corporate (44%)
- Other (4%)
- Academic (45%)
INFORMATION FOR LIBRARIANS

INSTITUTIONAL & ACADEMIC SUBSCRIPTIONS
Academic pricing is set regardless of size or number of sites. All academic institutes receive 5 years of content.

CORPORATE
Corporate pricing is dependent on the size of the company and the number of sites. Corporate institutes receive 2 years of content (backfills of content are available upon request).

CONSORTIA
FSG works with consortia of various types and sizes and welcomes discussion with all consortium managers. COUNTER-compliant usage statistics are provided for each institution. The benefits for the consortium include discounts on list price. Members have the flexibility to select the publications they want to include, or FSG will work with the consortium to create customized packages.

INDEXING
FSG titles are abstracted and indexed in all the main databases including MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Scopus, Thomson’s Science Citation Index Expanded and Chemical Abstracts.

Services
- Flexible purchasing
- Accessible for all institution types
- COUNTER-compliant usage reports
- ATHENS & Shibboleth authentication compliant
- Reliable publishing platform
- Dynamic customer services
- Promotion tools upon request
- Collection leasing

For more information go to www.future-science-group.com
INSTITUTIONAL TRIALS

If you would like to trial our content, just get in touch. Trials can be on single publications or entire collections, the choice is yours. We will work with you to decide on the best time and duration for your institution.

During the trial period, you have:

- Full-text access to the titles you select
- Detailed usage statistics from our Atypon-backed platform
- Support from our in-house technical team
- Control over the duration, visibility and promotion of the trial

Fair usage limits apply. For more details speak to a member of our team.

To request trial access, contact us at: trials@future-science-group.com or on +44 (0)20 8371 6090
NEW WEBSITE

Our new fully responsive site ensures all users will have the same reader experience no matter which device they use. Plus, the new, intuitive interface and streamlined navigation will reduce the number of clicks needed for readers to reach their desired content. We’re sure our improvements will encourage all users to return even more frequently.
INTEGRATING SCIENCE WITH COMMUNICATION

OUR PUBLISHING PROCESS

FSG upholds the highest standards of editorial integrity, including disclosure and independent peer review. We adhere to the guidelines set by COPE and ICMJE, endorse CONSORT, and follow the recommendations set by GPP3, ensuring our authors and readers are in safe hands.

Our unique editorial model, with an in-house, London-based team, means there is a specialist point of contact available at all times. This makes it easy for you to reach an expert in your field, understand the potential of your research and work towards achieving your objectives, with each author receiving the support of a dedicated editor.

Our publishing process is reassuringly rigorous, with a minimum of three experts (one in-house specialist editor and a minimum of two external) reviewing each paper.

EDITORIAL BOARDS

All journals are supported through guidance from their Editorial Boards.

Our Editorial Board members represent the world’s most prestigious organizations, including:

- Cambridge University, UK
- Harvard University, USA
- Monash University, Australia
- Karolinska Institute, Sweden
- Kyoto University, Japan
- Cancer Research UK, UK
A global network of researchers, practitioners and policy makers

READERSHIP

Our journal readership spans specialists in bioscience and medical practice across the globe.

Our key reader groups are:

- Clinical, basic and translational researchers in academia, industry, hospitals and government research organizations
- Clinicians in primary and secondary care, including: cardiologists, neurologists and oncologists
- Policy and decision makers in government and industry
- Those with an interest in pharmaceutical patents/intellectual property

FUTURE MEDICINE
www.futuremedicine.com
25 journals
Last 12 months*:
- 2.7 million abstract views
- 833,000 full-text downloads
- Global coverage

FUTURE SCIENCE
www.future-science.com
6 journals
Last 12 months*:
- 1.2 million abstract views
- 349,000 full-text downloads
- Global coverage

*as of June 30, 2016

SERVICES

To discuss your needs contact j.walker@future-science-group.com
MAKING THE MOST OF YOUR ARTICLE

MAXIMIZING YOUR RESEARCH

Whether you’re looking to publish clinical trial results, describe the design of a new study or provide an in-depth review, our team will support you fully before, during and after publication.

We are happy to work with both academic key opinion leaders as well as industry authors, as we recognize they are also among the leading experts in their field.

In addition to offering presubmission advice, we will assist you with journal selection for a broad range of article types, including:

ORIGINAL RESEARCH
- Pre- and post-registration studies
- Comparative effectiveness research
- Observational studies
- Clinical trial methodologies
- Cost–effectiveness/HEOR studies
- Negative data
- Evidence-based medicine and real-world data

REVIEWS
- Narrative reviews
- Unmet medical needs
- Multidisciplinary approaches to care
- Consensus and treatment guidelines
- Management perspectives
- Therapeutic overviews
- Drug, device and vaccine evaluations
- Commentaries on key clinical studies
- Systematic reviews
OPEN ACCESS

Publishing an article Open Access increases the readers it is able to reach, along with the recognition for you and your organization.

Open Access articles have significantly higher readership and usage than articles behind the subscription barrier.

All FSG subscription journals offer an Open Access option. FSG also publishes two fully Open Access journals – Concussion (P.9) and Future Science OA (P.14).

Authors can opt for our Gold Open Access option (CC BY-NC-ND), allowing unrestricted access to the online version of their article. This option is available for all article types except Drug Evaluation and Device Evaluation articles. We also offer reduced pricing for articles 12 months or older. For more information about pricing, contact j.walker@future-science-group.com.
ACCELERATED PUBLICATION

Our typical publication times are 14 to 16 weeks as standard (pending successful peer review).

But if you require earlier publication, you can publish in as little as 6 weeks through our Accelerated Publication service.

Accelerated Publication could help you stay ahead of the competition, or allow you to get some vital content out before an important conference. It will maximize the impact of your scientific endeavor, ensuring swifter access to your latest findings.

A fee per published page applies, and publication is, of course, still subject to approval by independent peer review.
Encourage readers to access and engage with your research

**ENAGO**

We partner with Enago to offer pre-submission editing services, including English editing and proofreading of scientific manuscripts for authors for whom English is a second language. For further information please contact our Editorial Director Laura Dormer at l.dormer@future-science-group.com. Or go to http://futuremedicine.enago.com http://futurescience.enago.com

**KUDOS**

All of our journals are available on the Kudos platform, a web-based service that helps researchers and their institutions and funders to maximize the visibility and impact of their published articles. Kudos provides a platform for assembling and creating information to help search filtering, for sharing information to drive discovery, and for measuring and monitoring the effect of these activities.

**SPONSORED ACCESS**

Sponsors or third parties wishing to make an article free to download from our website can provide access by paying the appropriate Sponsored Access fee. More information on the Sponsored Access option is available upon request.
“I would highly recommend submitting high-quality scientific manuscripts to [FSG’s] peer-reviewed journals.”
– Starr Grundy, Founding Partner, SD Scientific, USA

**SUPPLEMENTS**

Supplements are an ideal way to provide focused, added-value content for your target audience. Content may comprise:

- Symposia proceedings
- Abstract compilations
- Workshop summaries
- Roundtable discussions
- Article collections

All supplements follow the same standards of editorial integrity adopted by our journals, including disclosure, independent peer-review and publication guideline adherence (ICMJE/GPP3). Publication times are flexible depending on your needs and supplements can be published as early as 4 weeks from acceptance.

**REPRINTS**

Our dedicated in-house account managers are available throughout the publication process to discuss the dissemination of your research.

Reprints and ePrints are available in quantities as few as 100 copies, and we can customize them to include bespoke covers, logos and legal disclaimers.

We can deliver reprints to multiple locations worldwide, translating them into any language you require.

**DIGITAL SOLUTIONS**

To help meet your goals, we can enrich your research with digital options on our web platforms including:

- Audio/video abstracts
- Graphical abstracts
- Infographics and article snapshots
- Mechanism of action videos

Enhancing the value of our publications, we also have online networks, featuring journal articles as well as expert interviews and bespoke content. By featuring your article on our eCommunity sites you can further your reach to highly engaged groups. For more details on our eCommunities go to P.30.
“I have worked with FSG several times and have been consistently impressed with the positive experience.”
– Professor Giorgio Mustacchi, Università degli Studi di Trieste, Italy

SOCIAL MEDIA

All of our journals are integrated with Twitter, and many of our journals have sizable LinkedIn groups.

To maximize the impact of your article we can target niche groups with content exclusively devoted to your work.

ARTICLE METRICS

Leveraging both the Altmetric and Atypon platforms, we are able to provide granular article-level metrics for all our articles. Authors can look at the conversations around their paper and request usage data, making it easy for them to measure the impact and reach of their article.
HOW TO PUBLISH

Presubmission enquiries welcome
j.walker@future-science-group.com

Enago

Article ready for submission
Don’t forget!
You will need a signed author disclosure form, and a signed copyright form/OA license form online

Article submitted
Peer-review

Author revisions
eCOMMUNITIES

Niche communities that facilitate collaboration and innovation

Our eCommunities are built to meet the specific needs of niche scientific and medical communities. Enriched with high-value expert insight and integration with social media, our websites enhance the value of our publications.

Bioanalysis Zone, Oncology Central and Neurology Central have their own apps offering users personalized content from the past 30 days, including the latest news, journal articles and video in their field. This allows users to be specific about the topics they want to see, and to only receive the content notifications that really matter to them.

For more information about any of our eCommunities, contact r.hill@future-science-group.com

Bioanalysis Zone
www.bioanalysis-zone.com

With over 8000 registered users, Bioanalysis Zone is the market-leading online resource for the global bioanalytical community.

Bioanalysis Zone features an App.

Associated publication:
Bioanalysis
(MEDLINE-indexed, IF 2.813)

For eCommunity queries contact info@future-science-group.com
Oncology Central
www.oncology-central.com
Oncology Central offers easy access to breaking news and peer-reviewed articles in a clinician-curated environment.

Membership includes access to the peer-reviewed journals: *Breast Cancer Management*, *CNS Oncology*, *Colorectal Cancer*, *Hepatic Oncology*, *International Journal of Endocrine Oncology*, *International Journal of Hematologic Oncology*, *Lung Cancer Management* and *Melanoma Management*.

Oncology Central features an App.

Other associated publications:
*Epigenomics* (MEDLINE-indexed, IF 4.044)
*Future Oncology* (MEDLINE-indexed, IF 2.129)
*Immunotherapy* (MEDLINE-indexed, IF 2.083)

Neurology Central
www.neurology-central.com
Uniting all aspects of neurology, Neurology Central provides a high-quality platform that makes it easy to stay up-to-date with the latest developments in the field.

Membership includes access to the peer-reviewed journals: *CNS Oncology*, *Concussion*, *Future Neurology*, *Neurodegenerative Disease Management* and *Pain Management*.

Neurology Central features an App.

For more information go to www.future-science-group.com
MedChemNet
www.medchemnet.com
Bringing together medicinal chemistry professionals to discuss the latest research in this field, MedChemNet delivers news updates and features input from influential leaders, while acting as a platform for medicinal chemists to have their voices heard.

Associated publications:
Future Medicinal Chemistry (MEDLINE-indexed, IF 3.345)
Pharmaceutical Patent Analyst (MEDLINE-indexed)
Therapeutic Delivery (MEDLINE-indexed)

EpigenomicsNet
www.epigenomicsnet.com
The only network of its kind providing focused content and a platform for informative discussion on this cutting-edge subject.

Associated publications:
Biomarkers in Medicine (MEDLINE-indexed, IF 2.179)
Epigenomics (MEDLINE-indexed, IF 4.044)
Personalized Medicine (IF 1.00)
Pharmacogenomics (MEDLINE-indexed, IF 2.71)
RegMedNet
www.regmednet.com
RegMedNet provides a unique and unparalleled platform for the regenerative medicine community to share insights, discuss the latest research, and help move this pioneering field forward.

Associated publication:
Regenerative Medicine (MEDLINE-indexed, IF 2.602)

3DMedNet
www.3dmednet.com
From regulators and manufacturers to surgeons and bioengineers, 3DMedNet is a network that unites all members of this diverse community, enabling the connection and collaboration to help this exciting field move forward at an even faster rate.

Associated publication:
Journal of 3D Printing in Medicine (New in 2016)
“A big factor in making our webinar successful was the promotion and willingness of FSG to try new ideas to push registrations up.”
— Marketing Communications Manager, Thermo Fisher Scientific

SPONSORSHIP & ADVERTISING

There are now so many opportunities to communicate with people it is sometimes hard to know the most effective way to reach your particular target audience. At FSG, we offer our genuine insight into scientific communities to help you make sure your campaign reaches the right people in the right way.

Every project begins with an understanding of your goals. With our broad portfolio of journals, eCommunities and client opportunities we then create personalized and targeted campaigns that focus on your potential customers. With our in-house editorial and design teams we can offer you dedicated support to make sure the optimal message is delivered.

We want your campaign to be a success and know how important it is to be able to define your ROI; with this in mind we provide a detailed analytics report for every project we undertake to help you justify your marketing spend and plan your future campaigns.

For Bioanalysis Zone and MedChemNet enquiries, please contact: Sarah Bishop at: s.bishop@future-science-group.com

For all other eCommunity enquiries as well as journal sponsorship and advertising opportunities, please contact: Andy Kemp at: a.kemp@future-science-group.com

Sponsorship opportunities include:

- Webinars
- Sponsored audio and video recordings
- Product and company listings
- Symposia, conference reports and special issues
- Article reprints
- Sponsored access
- Sponsored subscriptions
- Targeted advertising placements
- Expert interviews and opinion
- Spotlights
- Surveys and polls
Contact us

For more information about our services contact:
j.walker@future-science-group.com

For more information about our journals or eCommunities contact:
info@future-science-group.com

For more information about institutional trials contact:
trials@future-science-group.com